News | December 06, 2007

Cardinal Health Launches Battle-Tested, Life-Saving Dressings for Acute Care Professionals

December 7, 2007 - Cardinal Health and HemCon Medical Technologies Inc. this week announced the availability of co-labeled chitosan-based hemorrhage control dressings to acute care professionals as part of an exclusive, four-year distribution agreement.

Cardinal Health now offers various sizes of the HemCon Bandage and ChitoFlex dressings to first responders and medical professionals in emergency rooms, trauma care, and cardiac catheterization labs.

Using HemCon's unique chitosan technology, antibacterial HemCon dressings control bleeding by becoming extremely sticky when in contact with blood. The adhesive-like action seals the wound and attracts red blood cells to the bandage, forming a seal that stops hemorrhaging independent of the clotting cascade. The bandages are effective on high-pressure, high-flow arterial bleeds. The hemostatic HemCon Bandages and ChitoFlex dressings are available in multiple sizes.

HemCon products have been used by the U.S. military since 2003, and, according to the U.S. Army Surgeon General's office, the HemCon Bandage has a 97 percent effective rate in controlling bleeding on the battlefield. HemCon recently redesigned its bandages to meet the specific needs of civilian trauma and emergency medicine.

All HemCon dressings are fabricated from chitosan, a naturally occurring, biocompatible polysaccharide derived from shrimp shells. The shrimp shells are processed, chemically treated, made into bandage form and then sterilized.

For more information:

Related Content

angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices| September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device

A close up view of the Rex Medical Closer Vascular Sealing System components.

Technology | Vascular Closure Devices| August 03, 2016
August 3, 2016 — The U.S.
Vivasure Medical, PerQSeal, vascular closure device, CE Mark
News | Vascular Closure Devices| January 18, 2016
Vivasure Medical announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable...
News | Hemostasis Management| January 06, 2016
The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which certain subsidiaries...
News | Vascular Closure Devices| December 16, 2015
Scientists at CBSET have presented preclinical evidence that the Manta Large Bore Vascular Closure Device (VCD) from...
platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Cartoon representation of a deformable platelet-like particle with fibrin nanobodies attached

Feature | Antiplatelet and Anticoagulation Therapies| July 13, 2015
Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles...
News | March 30, 2015
The Medicines Company announced that the European Commission has granted marketing authorization for two acute care...
Feature | March 02, 2015
Cardinal Health announced plans to acquire Johnson & Johnson’s Cordis business, a leading global manufacturer of...
Overlay Init